Fig. 1.

LS mean changes from baseline to week 24 among patients in DISCOVER-2 with active psoriatic arthritis and investigator-verified, imaging-confirmed sacroiliitis in BASDAI, spinal pain, and mBASDAI scores (A); mean changes from baseline to weeks 24, 52, and 100 in BASDAI (B), spinal pain (C), and mBASDAI (D) scores; and the proportions of patients achieving a BASDAI 50 response at weeks 24, 52, and 100 (E). Through week 24, treatment failure rules were applied for categorial endpoints, and LS mean changes were determined utilizing MMRM. After week 24, patients with missing data were considered nonresponders or to have no change from baseline (nonresponder imputation; NRI). Treatment group comparisons (each guselkumab group vs. placebo at week 24) were performed for LS mean changes and BASDAI 50 response. BASDAI Bath Ankylosing Spondylitis Disease Activity Index, BASDAI 50 ≥ 50% improvement in BASDAI, GUS guselkumab, LS least squares, mBASDAI modified BASDAI excluding Question #3, MMRM mixed-effect model for repeated measures, NRI nonresponder imputation, PBO placebo, Q Question, Q4W/Q8W every 4/8 weeks. Unadjusted p value vs. placebo: * < 0.001, **p < 0.05